Japanese postmarketing surveillance of clopidogrel for patients with non-ST-segment-elevation acute coronary syndrome indicated for percutaneous coronary intervention (J-PLACE NSTE-ACS)

被引：3

作者：

Morino Y. ^{[1
]}

Ako J. ^{[2
]}

Kobayashi M. ^{[3
]}

Nakamura M. ^{[4
]}

机构：

[1] Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Morioka

[2] Department of Cardiovascular Medicine, Kitasato University, Kanagawa

[3] Medical Operations, Tokyo, Sanofi K.K.

[4] Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo

来源：

Cardiovascular Intervention and Therapeutics | 2014年 / 29卷 / 2期

关键词：

Clopidogrel; NSTE-ACS; Postmarketing surveillance;

D O I：

10.1007/s12928-013-0229-1

中图分类号：

学科分类号：

摘要：

Clopidogrel in combination with aspirin has been a standard therapy for patients who have undergone percutaneous coronary intervention. The present study was conducted as a postmarketing surveillance, for the purpose of assessing the safety and efficacy of clopidogrel in real clinical practice in patients with non-ST-segment-elevation acute coronary syndrome (NSTE-ACS). Subjects were registered between March 2008 and December 2010, and as a result, patients not only with NSTE-ACS but also other types of ischemic heart diseases were enrolled. Data on off-label subjects were used only in safety evaluation. After excluding patients with inappropriate clinical report forms, 3,673 patients with non-ST-segment-elevation myocardial infarction, unstable angina, STEMI, stable angina, or old myocardial infarction were observed for safety evaluation. Efficacy was assessed in 2,562 of the 3,673 patients with NSTE-ACS. Aspirin was concomitantly prescribed to 3,615/3,673 (98.6 %) of the safety group, and 2,374/3,673 (64.6 %) received a loading dose of clopidogrel. During a maximum follow-up period of 12 months, 397 (10.8 %) of the 3,673 patients experienced adverse drug reactions (ADRs), of whom 145 (4.0 %) had serious conditions, as classified by the investigators. The most frequently observed ADRs were hepatobiliary and gastrointestinal disorders. Bleeding adverse events were observed in 138 patients (3.8 %) and 80 cases (2.2 %) were considered as serious. The 1-year cumulative incidence of major adverse cardiovascular events and major adverse cardiac and cerebrovascular events in the patients with NSTE-ACS were estimated to be 11.6 and 12.2 %, respectively. Serious AEs that substantially affect the safety profile of clopidogrel were not confirmed. © 2013 Japanese Association of Cardiovascular Intervention and Therapeutics.

引用

页码：123 / 133

页数：10

共 30 条

[1]

Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, pp. 494-502, (2001)

[2]

Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., Et al., Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet, 366, pp. 1607-1621, (2005)

[3]

Fox K.A.A., Mehta S.R., Peters R., Zhao F., Lakkis N., Gersh B.J., Et al., Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trial, Circulation, 110, pp. 1202-1208, (2004)

[4]

Sabatine M., Cannon C., Gibson C., Lopez-Sendon J., Montalescot G., Theroux P., Et al., Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, N Engl J Med, 352, pp. 1179-1189, (2005)

[5]

Wallentin L., Becker R.C., Butaji A., Cannon C.P., Emanuelsson H., Held C., Et al., Ticagrelol versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 361, pp. 1045-1057, (2009)

[6]

Smith Jr. S.C., Benjamin E.J., Bonow R.O., Braun L.T., Creager M.A., Franklin B.A., Et al., AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from American Heart Association and American College of Cardiology Foundation, Circulation, 124, pp. 2473-2485, (2011)

[7]

King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., Jacobs A.K., Morrison D.A., Williams D.O., Et al., Writing Group to review new evidence and update the ADD/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, writing on behalf of the 2005 Writing Committee. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline, Circulation

[8]

Maussa I., Oetgen M., Roubin G., Colombo A., Wang X., Iyer S., Et al., Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation, Circulation, 99, pp. 2364-2366, (1999)

[9]

Brertrand M.E., Rupprecht H.-J., Urban P., Gershlick A.H., Double-blind study of the safety of clopidogrel with or without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS), Circulation, 102, pp. 624-629, (2000)

[10]

Fischer M.J., Ho P.M., McDermott K., Lowy E., Parikh C.R., Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome, BMC Nephrol, 14, (2013)

← 1 2 3 →